BCA
FLNA

Berman Capital Advisors’s Filana Therapeutics FLNA Stock Holding History

Berman Capital Advisors’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$56K Sell
914
-80
-8% -$6.68K 0.01% 635
2021
Q2 		$84K Hold
994
– – 0.01% 429
2021
Q1 		$44K Hold
994
– – 0.01% 527
2020
Q4 		$6K Hold
994
– – ﹤0.01% 1099
2020
Q3 		$11K Buy
+994
New +$4.48K ﹤0.01% 765

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Berman Capital Advisors's FLNA Position: Q3 2021 in Review

Berman Capital Advisors reduced its Filana Therapeutics (FLNA) stake by 8% in Q3 2021, selling an estimated $6.68K and leaving 914 shares worth $56K. The position accounts for 0.01% of the portfolio, ranked #635.

Berman Capital Advisors first reported a position in FLNA in Q3 2020 and has held it in 5 quarters since. The position peaked at $84K in Q2 2021. 180 funds tracked by Wall St. Rank hold FLNA as of Q3 2021.

  • Berman Capital Advisors held 914 shares of Filana Therapeutics worth $56K as of Q3 2021.
  • Berman Capital Advisors sold 80 Filana Therapeutics shares in Q3 2021, an estimated $6.68K.
  • Filana Therapeutics made up 0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #635 holding.
  • Berman Capital Advisors first reported a position in Filana Therapeutics in Q3 2020 and has held it in 5 quarters since.
  • Berman Capital Advisors's Filana Therapeutics position peaked at $84K in Q2 2021.
  • 180 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.